[go: up one dir, main page]

NO20070334L - 4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer - Google Patents

4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer

Info

Publication number
NO20070334L
NO20070334L NO20070334A NO20070334A NO20070334L NO 20070334 L NO20070334 L NO 20070334L NO 20070334 A NO20070334 A NO 20070334A NO 20070334 A NO20070334 A NO 20070334A NO 20070334 L NO20070334 L NO 20070334L
Authority
NO
Norway
Prior art keywords
protein kinase
kinase inhibitors
disubstituted pyrimidines
pyrimidines
disubstituted
Prior art date
Application number
NO20070334A
Other languages
English (en)
Inventor
Thomas Beckers
Thomas Maier
Wolfgang Wirschun
Matthias Herdemann
Josef Stadlwieser
Thomas Baer
Thomas Ciossek
Armin Zuelch
Ulrich Graedler
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of NO20070334L publication Critical patent/NO20070334L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Oppfinnelsen vedrører nye pyrimidinderivater med formel (I), som er effektive proteinkinaserinhibitorer, spesielt av én eller flere isoformer av proteinkinasen B/Akt. ?? ?? ?? ??
NO20070334A 2004-06-28 2007-01-18 4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer NO20070334L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103011 2004-06-28
EP05102355 2005-03-23
PCT/EP2005/053019 WO2006000589A1 (en) 2004-06-28 2005-06-28 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20070334L true NO20070334L (no) 2007-03-28

Family

ID=34973043

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070334A NO20070334L (no) 2004-06-28 2007-01-18 4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer

Country Status (16)

Country Link
US (1) US7879853B2 (no)
EP (1) EP1763526B1 (no)
JP (1) JP5065017B2 (no)
KR (1) KR20070027723A (no)
CN (1) CN1972934A (no)
AT (1) ATE434614T1 (no)
AU (1) AU2005256659A1 (no)
BR (1) BRPI0512547A (no)
CA (1) CA2570552A1 (no)
DE (1) DE602005015110D1 (no)
ES (1) ES2328601T3 (no)
IL (1) IL179883A0 (no)
MX (1) MXPA06014747A (no)
NO (1) NO20070334L (no)
WO (1) WO2006000589A1 (no)
ZA (1) ZA200609637B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6907921B2 (en) 1998-06-18 2005-06-21 3M Innovative Properties Company Microchanneled active fluid heat exchanger
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2008016203A (es) 2006-07-06 2009-01-27 Array Biopharma Inc Ciclopenta [d] pirimidinas como inhibidores de la proteina cinasa akt.
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
US20090012434A1 (en) * 2007-07-03 2009-01-08 Anderson Robert S Apparatus, method, and system to treat a volume of skin
US7982036B2 (en) * 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
MY179607A (en) 2011-04-01 2020-11-11 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
BR112013025397A2 (pt) 2011-04-01 2019-09-24 Deepak Sampath combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero
AU2012321091B2 (en) * 2011-10-28 2016-05-12 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
TW201325593A (zh) * 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
DK2834231T3 (en) * 2012-04-04 2016-04-18 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
JP2016509012A (ja) 2013-02-08 2016-03-24 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｅｒｋ阻害剤およびそれらの使用
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN103483250B (zh) * 2013-10-08 2015-07-22 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN103601675B (zh) * 2013-10-08 2015-10-28 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
CN113509471B (zh) * 2021-07-19 2023-06-13 中国药科大学 Akt2抑制剂在制备治疗阿霉素引发心肌损伤药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (no) 1994-11-12 1997-12-01 Zeneca Ltd
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU2735201A (en) * 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
BR0113165A (pt) 2000-08-08 2003-07-15 Ortho Mcneil Pharm Inc Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
AR035967A1 (es) * 2001-05-18 2004-07-28 Altana Pharma Ag Un compuesto de piridilmetilaminopirimidina, un medicamento que lo comprende y el uso del mismo
WO2003037891A1 (en) * 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
MXPA04004177A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de amida como inhibidores de la glicogeno cintasa cinasa 3-beta.
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4508645B2 (ja) 2002-01-04 2010-07-21 ザ ロックフェラー ユニバーシティー アミロイド−βペプチド関連疾患の予防および治療用の組成物および方法
MXPA05005477A (es) * 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
CA2553513A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain

Also Published As

Publication number Publication date
JP5065017B2 (ja) 2012-10-31
US20070208034A1 (en) 2007-09-06
CN1972934A (zh) 2007-05-30
KR20070027723A (ko) 2007-03-09
BRPI0512547A (pt) 2008-03-25
DE602005015110D1 (de) 2009-08-06
EP1763526B1 (en) 2009-06-24
MXPA06014747A (es) 2007-02-16
WO2006000589A8 (en) 2006-11-16
ES2328601T3 (es) 2009-11-16
US7879853B2 (en) 2011-02-01
JP2008504251A (ja) 2008-02-14
CA2570552A1 (en) 2006-01-05
EP1763526A1 (en) 2007-03-21
ZA200609637B (en) 2008-08-27
IL179883A0 (en) 2007-05-15
WO2006000589A1 (en) 2006-01-05
ATE434614T1 (de) 2009-07-15
AU2005256659A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
NO20070334L (no) 4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
DK1567522T3 (da) Pyrimidinforbindelser
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
WO2005116025A3 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
WO2007079164A3 (en) Protein kinase inhibitors
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
DK2089369T3 (da) 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
ATE508126T1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
WO2006083673A3 (en) Pyridine derivatives useful as inhibitors of c-jun n-terminal kinases
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application